Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | SHMT1 | P34896 | 2/20 | 0.41 |
| ▸ | SHMT2 | P34897 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6474873 | 0.92 | KMT2A (0.41) | KMT2AMEN1GAAKDM4ELPAR1 | |
| SCHEMBL6480025 | 0.89 | GAA (0.44) | KMT2AMEN1SHMT1SHMT2GAA | |
| SCHEMBL6474846 | 0.88 | MEN1 (0.42) | KMT2AMEN1SHMT1SHMT2GAA | |
| SCHEMBL6475325 | 0.88 | MEN1 (0.41) | KMT2AMEN1SHMT1SHMT2GAA | |
| SCHEMBL8906080 | 0.87 | SHMT1 (0.48) | KMT2ASHMT1SHMT2 | |
| SCHEMBL8655612 | 0.87 | P2RX7 (0.43) | KMT2ASHMT1SHMT2LMNA | |
| SCHEMBL6474979 | 0.87 | LPAR1 (0.51) | KMT2AMEN1SHMT1SHMT2GAA | |
| SCHEMBL6479959 | 0.87 | LPAR1 (0.44) | KMT2AMEN1SHMT1SHMT2GAA | |
| SCHEMBL6483723 | 0.86 | LPAR1 (0.52) | KMT2AMEN1SHMT1SHMT2GAA | |
| SCHEMBL6473570 | 0.86 | LPAR1 (0.52) | KMT2AMEN1SHMT1SHMT2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6939888-B2 | 1-H-3-arylpirrolidine-2,4-dione derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2005-09-06 | — | — | US | disclosed |
| US-20040019061-A1 | 1-H-3-arylpirrolidine-2,4-dione derivatives | FISCHER REINER (DE) | 2004-01-29 | — | — | US | disclosed |
| US-6472419-B1 | 1-H-3-aryl-pyrrolidine-2, 4-dione derivatives as pest-control agents | BAYER AKTIENGESELLSCHAFT (DE) | 2002-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019061-A1 | 1-H-3-arylpirrolidine-2,4-dione derivatives | PRXL2A, DDT, CYP4B1 | KMT2A 2190/4885MEN1 3194/4885SHMT1 4110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.